CD8A and neoplasm: Indeed, no significant differences in the proportion of infiltrating CD8+ T cells were observed among any other IPTG-treated βA versus Ctrl groups in either the presence or absence of shLuc, in line with our aforementioned observation that treatment with IPTG alone also blunted the βA-induced tumor growth advantage.